logo
logo
FUNDING SIGNALS

Real Signals. Real Leads. Real Deals.

The only platform that turns real-time signals into your perfect leads

Know Who, Why, and When to reach out — instantly.

FundzWatch™ AI Scoring
10-25 leads daily
Real-time alerts
★★★★★
4.8/5 on G2• High Performer Fall 2025
Used by teams at LinkedIn, HubSpot & Oracle
🔒 app.fundz.net

TechCorp

📍 San Francisco👥 85
92
Post-Funding
⭐ Ideal Match

Just raised $40M Series B - high purchase intent window

Immunity Bio announced it raised $10.7 Million in an initial filing from an offering of $10.7 Million

Jul 22, 2022•about 3 years ago

Amount Raised

$10.7 Million

San DiegoBiotechnology

Company Information

Company

ImmunityBio

Location

3530 John Hopkins Court

San Diego, California, United States

About

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory.

Company News

(10 articles)
Mon, 02 Jun 2025 07:00:00 GMT

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Yahoo Finance

Tue, 19 Aug 2025 07:00:00 GMT

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - Business Wire

Mon, 07 Apr 2025 07:00:00 GMT

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire

Fri, 25 Jul 2025 07:00:00 GMT

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - Business Wire

Fri, 25 Jul 2025 07:00:00 GMT

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Business Wire

Wed, 26 Mar 2025 07:00:00 GMT

ImmunityBio to Host Investor Day - Business Wire

Mon, 11 Aug 2025 07:00:00 GMT

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Business Wire

Mon, 21 Apr 2025 07:00:00 GMT

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - Business Wire

Wed, 29 Jan 2025 08:00:00 GMT

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire

Mon, 07 Jul 2025 07:00:00 GMT

Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

FundzWatch™ Score

71
High Activity
8 total signals

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech